[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644423":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":37,"locations":44,"responsibleParty":59,"collaborators":42,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":42,"eligibilityCriteria":66,"healthyVolunteers":63,"sex":67,"minAge":68,"maxAge":42,"enrollmentInfo":69,"targetDuration":42,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":82,"whyStopped":42,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Wake Forest University Health Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"topical ruxolitinib (Opzelura)","EXPERIMENTAL","patients are directed to apply topical ruxolitinib (Opzelura) twice daily to all affected areas until clear, then as needed.",[13],"Drug: ruxolitinib",{"label":15,"type":16,"description":17,"interventionNames":18},"topical ruxolitinib (Opzelura) and Complex Regimen","ACTIVE_COMPARATOR","patients will be directed to apply topical ruxolitinib (Opzelura) twice daily to all affected areas until clear, then as needed. Patients will also be provided an Eczema Action Plan (EAP) with recommended lifestyle recommendations, including what cleanser to use, allergen avoidance, use of moisturizers, and bathing practices as determined by disease severity.",[19],"Drug: ruxolitinib and an Eczema Action Plan",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","ruxolitinib","patients are directed to apply topical ruxolitinib (Opzelura) twice daily to all affected areas until clear, then as needed",[9],[27],"Opzelura",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"ruxolitinib and an Eczema Action Plan","patients will be directed to apply topical ruxolitinib (Opzelura) twice daily to all affected areas until clear, then as needed. Patients will also be provided an Eczema Action Plan (EAP) with recommended lifestyle recommendations, including what cleanser to use, allergen avoidance, use of moisturizers, and bathing practices as determined by disease severity",[15],[27],[34],{"name":35,"affiliation":5,"role":36},"Steven R Feldman, MD, PhD","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Irma Richardson, MHA","CONTACT","336-716-2903",null,"irma.richardson@advocatehealth.org",[45],{"facility":5,"status":42,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Winston-Salem","North Carolina","27157","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-80.24422,36.09986,{"lat":55,"lon":54},[58],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},{"type":60,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100644423","phase-4-opzelura-experience-study-100644423",false,"NCT07661979","Opzelura Experience Study","Inclusion Criteria:\n\n* Patients ≥2 years of age\n* Patients with a current diagnosis of atopic dermatitis that is mild-to-moderate in severity and in ≥2 body areas\n* Patients with up to 20% total body surface area involvement\n* Women of childbearing age taking\u002Fusing a contraceptive\n\nExclusion Criteria:\n\n* Patients without a current diagnosis of atopic dermatitis\n* Patients who are prescribed changing systemic medications or treatments (phototherapy, biologics) for atopic dermatitis\n* Patients who would require use of other topical medications for other diagnoses (tretinoin, clindamycin)\n* Patients with areas of skin with active infection\n* Patients who are pregnant","ALL","2 Years",{"count":70,"type":71},50,"ESTIMATED","INTERVENTIONAL",[74],"PHASE4","Atopic dermatitis is a common multifactorial skin disease. Topicals are the mainstay of treatment, but adherence to topicals is often abysmal, possibly worsened by the complexity of recommended treatment algorithms. Giving patients a simple, one drug approach may be advantageous.",[77],"Atopic Dermatitis",[79,80,81],"skin atrophy","treatment adherence","topical medications","NOT_YET_RECRUITING","2026-06-17",{"date":85,"type":86},"2026-06-23","ACTUAL",{"date":88,"type":71},"2026-08",{"date":90,"type":71},"2027-10",{"name":5,"class":6},1]